Bupropion for the Treatment of Methamphetamine Dependence - 1

Bupropion for the Treatment of Methamphetamine Dependence

The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence

A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.

Inclusion Criteria:

• Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis
• Subject must be willing to comply with study procedures.
• Ability to verbalize understanding of consent form, provide written consent, and verbalize willingness to complete study procedures
• Be able to comply with protocol requirements

Exclusion Criteria:

• Please contact site for more information.